Key Stage 1

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Bispecific monoclonal antibody, Patient, FDA, PD-L1, Trial of the century, IND, Therapy, Paclitaxel, G&A, AUC, PD-1, Doctor of Philosophy, Entrepreneurship, Stage 2, Development, CRC, Key Stage 1, Research and development, DLL4, Safety, Management, Fine chemical, Nursing, Pharmaceutical industry, Cryptocurrency, Research, Compass, MD, BTC

Transition to take place on January 9th 2024

Key Points: 
  • Transition to take place on January 9th 2024
    Ended the third quarter with $164 million in cash and marketable securities, providing cash runway for the company into 2026
    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date, 2023 financial results.
  • During the first nine months of 2023, the Company used $28 million of cash to fund operations.
  • R&D expenses were $8.8 million for the quarter ended September 30, 2023, as compared to $9.8 million for the same period in 2022, a decrease of approximately $1.0 million or 10%.
  • G&A expenses were $3.1 million for the quarter ended September 30, 2023, as compared to $2.8 million for the same period in 2022, an increase of $0.3 million or 10%.

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 3, 2023
Therapy, CRC, G&A, DLL4, Doctor of Philosophy, Trial of the century, Stage 2, Key Stage 1, Patient, Compass, Paclitaxel, Entrepreneurship, BTC, IND, Safety, Nursing, Pharmaceutical industry, Cryptocurrency, MD

Phase 2 study of CTX-009 in patients with advanced biliary tract cancers (BTC); top line data from this study is now expected in the second half of 2024

Key Points: 
  • Phase 2 study of CTX-009 in patients with advanced biliary tract cancers (BTC); top line data from this study is now expected in the second half of 2024
    Ended the second quarter with $169 million in cash and marketable securities, providing cash runway for the company into 2026
    BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported second quarter, and year-to-date, 2023 financial results.
  • During the first half of 2023, the Company used $22 million of cash to fund operations.
  • R&D expenses were $10.2 million for the quarter ended June 30, 2023, as compared to $5.9 million for the same period in 2022, an increase of approximately $4.4 million or 74%.
  • G&A expenses were $3.1 million for the quarter ended June 30, 2023 and 2022.

ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071 for Hypoxic Ischemic Encephalopathy in Newborns

Retrieved on: 
Tuesday, August 1, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, COPD, Graft-versus-host disease, Medicine, Doctor of Philosophy, STAR, Pharmacokinetics, HIE, C1, Oxygen, Hypothermia, Brain, DSM-IV codes, Rodels-Realta railway station, Asphyxia, Key Stage 1, Hypoxia (medical), Patient, MPO, Immune system, Neutrophil extracellular traps, Observation, Mortality, MPH, Death, Disease, Pharmaceutical industry, Safety, MD, Infant

ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening rare diseases by harnessing the power of the immune system, today announced dosing of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE) in newborns.

Key Points: 
  • ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening rare diseases by harnessing the power of the immune system, today announced dosing of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE) in newborns.
  • After completion of Stage 1, participants will transition to Stage 2 of the study for long-term observation out to 24 months of age.
  • The initial loss of oxygen and the dysregulated inflammatory process that follows causes damage to the brain and other organs.
  • This acute disease often results in death or moderate-to-severe cognitive and physical disability, with life-long impacts on both the newborn and the newborn’s family.

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

Retrieved on: 
Monday, July 24, 2023
HAT, Male, Suramin, PRV, Natural history, HIV, Diarrhea, Hospital, Priority review, Autism spectrum, Survival, African, NDA, Weakness, Record, Hope, Chest pain, Federal Food, Drug, and Cosmetic Act, Cough, GAO, TBG, Key Stage 1, Patient, ASD, Northrop Grumman B-2 Spirit, Physician, Lymph, Arsenic, Diagnosis, APT, FDA, Headache, TBR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Roger Hawkins (drummer), Death, Somnolence, FD, Food, Safety, Fatigue, Disease, Malaria, Pharmaceutical industry, Nursing

These records included data from a few weeks of hospitalization while they were being evaluated and the diagnosis of TBR HAT confirmed.

Key Points: 
  • These records included data from a few weeks of hospitalization while they were being evaluated and the diagnosis of TBR HAT confirmed.
  • As their conditions began to deteriorate, patients were often treated with arsenic or related compounds, sent to a Sleeping Sickness Hospital, or sent home to die with their families.
  • The natural history records do not include long term outcomes data for many of the patients.
  • One suramin-treated patient tested positive for HIV (only 23% tested) and 16/76 (21%) of patients tested were positive for malaria.

Prosimo Disrupts MCN Market by Making Multi-Cloud Connectivity Free

Retrieved on: 
Wednesday, June 28, 2023
Cloud, DevOps, MCN, Platform as a service, Policy, Research, Organization, Key Stage 1, Friction, VPC, SAN, Application development, VNET, ESG, TCO, Networking hardware, Google Cloud Connect, Network equipment provider, Video game, Cryptocurrency

SAN JOSE, Calif., June 28, 2023 /PRNewswire/ -- Prosimo launches Prosimo MCN Foundation, an industry-disrupting free Multi-Cloud Networking solution powered by its Cloud-Native Full Stack Platform. Prosimo has received accolades from Fortune 500 financial service companies and prominent enterprises for its exceptional cloud-native architecture. The MCN Foundation offering has garnered praise for its ability to deliver significant cost savings, surpassing $100,000 compared to commercial alternatives. By adopting this solution, businesses move to advanced MCN solutions from Prosimo that can achieve a remarkable 30-50% reduction in the total cost of ownership (TCO), potentially resulting in savings of millions of dollars.

Key Points: 
  • MCN Foundation reduces Cloud Connectivity management from weeks to minutes with core capabilities: Seamless onboarding, cloud discovery, VPC/VNET connectivity, access policies, and real-time troubleshooting across any cloud.
  • SAN JOSE, Calif., June 28, 2023 /PRNewswire/ -- Prosimo launches Prosimo MCN Foundation, an industry-disrupting free Multi-Cloud Networking solution powered by its Cloud-Native Full Stack Platform.
  • Prosimo has received accolades from Fortune 500 financial service companies and prominent enterprises for its exceptional cloud-native architecture.
  • The MCN Foundation offering has garnered praise for its ability to deliver significant cost savings, surpassing $100,000 compared to commercial alternatives.

Prosimo Disrupts MCN Market by Making Multi-Cloud Connectivity Free

Retrieved on: 
Wednesday, June 28, 2023
Cloud, DevOps, MCN, Platform as a service, Policy, Research, Organization, Key Stage 1, Friction, VPC, SAN, Application development, VNET, ESG, TCO, Networking hardware, Google Cloud Connect, Network equipment provider, Video game, Cryptocurrency

SAN JOSE, Calif., June 28, 2023 /PRNewswire/ -- Prosimo launches Prosimo MCN Foundation, an industry-disrupting free Multi-Cloud Networking solution powered by its Cloud-Native Full Stack Platform. Prosimo has received accolades from Fortune 500 financial service companies and prominent enterprises for its exceptional cloud-native architecture. The MCN Foundation offering has garnered praise for its ability to deliver significant cost savings, surpassing $100,000 compared to commercial alternatives. By adopting this solution, businesses move to advanced MCN solutions from Prosimo that can achieve a remarkable 30-50% reduction in the total cost of ownership (TCO), potentially resulting in savings of millions of dollars.

Key Points: 
  • MCN Foundation reduces Cloud Connectivity management from weeks to minutes with core capabilities: Seamless onboarding, cloud discovery, VPC/VNET connectivity, access policies, and real-time troubleshooting across any cloud.
  • SAN JOSE, Calif., June 28, 2023 /PRNewswire/ -- Prosimo launches Prosimo MCN Foundation, an industry-disrupting free Multi-Cloud Networking solution powered by its Cloud-Native Full Stack Platform.
  • Prosimo has received accolades from Fortune 500 financial service companies and prominent enterprises for its exceptional cloud-native architecture.
  • The MCN Foundation offering has garnered praise for its ability to deliver significant cost savings, surpassing $100,000 compared to commercial alternatives.

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 4, 2023
Kansai Medical University, University, Therapy, Senior, CRC, CFO, Cholangiocarcinoma, EVP, Macrogen, Emergent, G&A, MBA, Dartmouth College, DLL4, Doctor of Philosophy, Arbutus Biopharma, Audit committee, Eli Lilly, Stage 2, Key Stage 1, Margetuximab, Patient, M.B.A, Sprint Corporation, Compass, Cancer, Paclitaxel, CEB, Entrepreneurship, Merck, BTC, Treasurer, R, SVP, Pembrolizumab, Safety, NYSE, HCC, BA, Certified Treasury Professional, Nursing, Management, Pharmaceutical industry, Medical device, MD

Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC).

Key Points: 
  • Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC).
  • Initial data expected in the third quarter of 2023
    Expanded the management team with the appointment of Minori Rosales, M.D.
  • Initial results from this study are expected in the third quarter of 2023
    In April 2023, the company appointed Minori Rosales, MD PhD, as Senior Vice President & Head of Clinical Development.
  • Prior to Emergent BioSolutions, from 2009-2017, Mr. Lindahl was Chief Financial Officer at CEB, a NYSE-listed technology company.

EQS-News: EcoGraf Limited:  Epanko Pre-Development Program Delivers Outstanding Results

Retrieved on: 
Monday, May 1, 2023
International Finance Corporation, Engineering, Peer review, ASX, FSE, FMK, Government, Key Stage 1, EGR, Independent engineer, OTCQX, Toyota GR engine, Project, Biophysical environment, Growth, Metallurgy, Framework agreement, Grid-style social management in China, BFS, SRK, Legislation, Risk management, Construction, Renewable energy, Limited

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • EcoGraf Limited (EcoGraf or the Company) (ASX: EGR; FSE: FMK; OTCQX: ECGFF) is pleased to report the results of its Epanko Graphite Project (‘Epanko’ or the ‘Project’) pre-development program and includes updated capital cost, operating cost, graphite pricing with all the material assumptions as detailed in the Bankable Feasibility Study (refer announcement dated 21 June 2017).
  • Epanko is positioned to become a world class graphite project located in Tanzania with the recent signing of the Epanko Framework Agreement which positions the Company to secure financing for a Final Investment Decision for the Project.
  • The results of the Epanko program position the Project to be a potential world class new graphite development, commencing with Stage 1 with the intention to expand and match the rapid growth forecast for battery graphite to support the global transition to clean energy.

Coringa Project Update

Retrieved on: 
Wednesday, March 22, 2023
Mining, LI, Novo Progresso, AIM, Guia, European Union (Withdrawal) Act 2018, Classification, TI, Bau, INCRA, Land, ANM, ECI, FUNAI, ILO, Key Stage 1, Indigenous and Tribal Peoples Convention, 1989, Gold, Nacional, Hearing, SRB, Project, TSX, Internal, News, LOG, Lease, EU, Coringa

Serabi Gold plc (AIM:SRB, TSX:SBI), the Brazilian-focused gold mining and development company, is pleased to provide an update on progress at its Coringa project(“the Project”) located in the Tapajos region of Para, Brazil.

Key Points: 
  • Serabi Gold plc (AIM:SRB, TSX:SBI), the Brazilian-focused gold mining and development company, is pleased to provide an update on progress at its Coringa project(“the Project”) located in the Tapajos region of Para, Brazil.
  • “As previously advised, we produced 1,103 ounces from Coringa during the period July 2022 to December 2022 by trucking high grade ore from Coringa to our Palito operation for processing.
  • Ore sorting test work on the Coringa ore has produced excellent results with between 45% and 50% reduction in the mass needing to be processed.
  • Despite this, land possession in the area where the Coringa Project is located has been subject to various challenges over the years.

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 15, 2023
Acquisition, Stage 2, Therapy, Patient, Paclitaxel, Pembrolizumab, Merck & Co., Neck, PFS, OS, Head, GMP, Compass, BTC, Completeness, CD137, PIPE, CRC, CBR, MBA, Key Stage 1, Melanoma, RECIST, Toxicology, Merck Sharp & Dohme Federal Credit Union, ORR, Safety, Doctor of Philosophy, IND, Merck, DOR, Entrepreneurship, Lung, Pharmaceutical industry, Nursing, Cryptocurrency, MD

“Compass made tremendous progress last year as we advanced the development of our three drug candidate programs.

Key Points: 
  • “Compass made tremendous progress last year as we advanced the development of our three drug candidate programs.
  • Development Pipeline Update and Highlights:
    In the second line setting, an ORR of 63.6% in 11 patients treated was observed
    In January 2023, announced first patient dosed in the U.S.
  • During 2022, the Company increased its cash position by $80.3 million from financing activities that generated net proceeds of $75.8 million.
  • Compass management will participate at four upcoming investor conferences:
    KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.